The FY2025 (Dec) proxy of Filana Therapeutics names 19 peer companies for pay. Among Filana Therapeutics and these peers, CEO pay was 10th highest of 11 and total shareholder return was 9th highest of 11.
10th highest of 11in Filana Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
9th highest of 11in Filana Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
Pay peer group, FY2025 (Dec) proxy
| Inhibikase Therapeutics | ||
| Avalo Therapeutics | ||
| Corbus Pharmaceuticals Holdings | ||
| Annexon | ||
| Larimar Therapeutics | ||
| Atea Pharmaceuticals | ||
| Eledon Pharmaceuticals | ||
| Protara Therapeutics | ||
| Inmune Bio | ||
| Skye Bioscience | ||
| Atossa Therapeutics | Not disclosed | Not disclosed |
| Cardiff Oncology | Not disclosed | Not disclosed |
| Climb Bio, Inc. | Not disclosed | Not disclosed |
| Coya Therapeutics | Not disclosed | Not disclosed |
| Jasper Therapeutics | Not disclosed | Not disclosed |
| Medicinova | Not disclosed | Not disclosed |
| Quince Therapeutics, Inc. | Not disclosed | Not disclosed |
| Sagimet Biosciences | Not disclosed | Not disclosed |
| Zura Bio | Not disclosed | Not disclosed |
PSU comparator group
The companies that relative total shareholder return is measured against for performance stock units.
| NASDAQ Biotechnology Index (index) | Not disclosed | Not disclosed |
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.